Novozymes sales up, growth down as expected for Q2
In Denmark, Novozymes has announced its results for the first half of FY 2014. Sales grew by 8% organically, but sales growth slowed as expected after a strong first quarter.
“It’s been a good first half for Novozymes”, says Novozymes CEO Peder Holk Nielsen. “Sales growth was in line with expectations and earnings were strong. For the full year, we maintain our outlook for sales growth, and profit is now expected to come in a little better than what we thought back in April. Looking beyond the financial performance, we’ve seen good progress in our innovation pipeline and portfolio of growth platforms in the first half of the year. In the second half, we’ll continue to concentrate our efforts on advancing both to further strengthen our ability to deliver double-digit sales growth.”
Category: Fuels
